Portfolio Update
The Board of OT2 VCT notes that Arecor Therapeutics plc (Arecor), which at 31 May 2021 was 42 % of the OT2 NAV of 27.17p/share was based on an Arecor share price of £2.26 which has now risen to £4.30 bid price as at market close on 23 September. In isolation, each 100p change in Arecor's share price has a 5p impact on the NAV of OT2 VCT.
The Board are in the process of preparing the accounts for the half year ending 31 August 2021, which will including further details of the valuation of the rest of the portfolio. These are expected to be issued in October.
For further information please contact: Lucius Cary 01865 784466
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages CI&T Inc Investors to Inquire About Securities Class Action Investigation – CINT
- Avis Budget Group to Announce First Quarter 2024 Results on May 1st
- Three From Lyons & Simmons Selected Among Best Lawyers in Dallas
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!